Andrew C. Hsieh
Showed, as first author in Davide Ruggero's lab, that oncogenic mTOR drives cancer metastasis by selectively translating a specific pro-invasion mRNA program
Professor, Fred Hutchinson Cancer Center; Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research (2026) · postdoc, UCSF (Davide Ruggero lab) · MD, Albert Einstein College of Medicine
Hsieh Lab, Fred Hutchinson Cancer Center (Seattle, Washington, USA) ↗ Lab lineagetrained under Davide Ruggero →
Portrait: Fred Hutchinson Cancer Center
As a postdoc with Ruggero (who has his own profile in the Atlas), Hsieh showed in a 2010 Cancer Cell paper (HSI2010) that 4E-BP1–eIF4E, not S6 phosphorylation, mediates oncogenic mTOR signaling. His first-author 2012 Nature paper with Ruggero (HSI2012) used ribosome profiling to show mTOR selectively translates pro-invasion mRNAs in prostate cancer; INK128 reversed the signature.
Now at Fred Hutch, studying translation-driven lineage plasticity in prostate cancer (2026 JCI paper).
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2010 | M | Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E HSI2010 4EBP–eIF4E axis, not S6 phosphorylation, mediates oncogenic mTOR signaling; druggable with PP242. |
| 2012 | M | The translational landscape of mTOR signalling steers cancer initiation and metastasis HSI2012 Ribosome profiling shows oncogenic mTOR selectively translates pro-invasion mRNAs driving prostate cancer metastasis. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Andrew C. Hsieh.
ShowHide
- Davide Ruggero 2 shared studies Showed that oncogenic mTOR signalling reprograms which mRNAs are translated, and that tumours become addicted to this through the 4E-BP–eIF4E axis. His UCSF lab found that mTOR-driven translation of a specific set of mRNAs promotes prostate cancer invasion and metastasis
- Kevan M. Shokat 2 shared studies Co-developed the ATP-competitive 'TORKinib' mTOR inhibitors that block both mTORC1 and mTORC2, and later, with Neal Rosen's lab at Memorial Sloan Kettering, RapaLink-1, a third-generation inhibitor that overcomes mTOR resistance mutations
- Matthew R. Janes Showed, as first author in David Fruman's lab, that a dual TORC1/2 kinase inhibitor kills leukemia cells with much weaker effects on normal lymphocytes than rapamycin
- Nicholas T. Ingolia Known for ribosome profiling, a method that reads out which messenger RNAs ribosomes are translating across a whole genome; the study in the Atlas used this approach to map mTOR-controlled translation in prostate cancer.
- Yi Liu Drug-discovery scientist who builds selective kinase inhibitors, including the active-site mTOR inhibitor INK128
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.